Skip to content

The prognostic value of serial monitoring of plasma soluble suppression of tumorigenicity 2 (sST2) in patients hospitalized with acute heart failure: a national multicenter clinical study

The prognostic value of serial monitoring of plasma soluble suppression of tumorigenicity 2 (sST2) in patients hospitalized with acute heart failure: a national multicenter clinical study

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000041226
Enrollment
Unknown
Registered
2020-12-22
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Heart Failure

Interventions

Gold Standard:N terminal pro B type natriuretic peptide (NT-proBNP).
suppression&#32
of&#32
tumorigenicity&#32
(sST2).

Sponsors

Fuwai Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: In this study, adult patients with AHF of different types and etiologies were selected. Referring to the Chinese guidelines for the diagnosis and treatment of heart failure 2018, the inclusion criteria of the subjects were as follows: 1. Patients over 18 years old. 2. Patients with typical symptoms and / or characteristics of heart failure: typical symptoms of heart failure include exertional dyspnea (such as chest tightness, suffocation, shortness of breath, etc.) after activity, paroxysmal dyspnea at night, sitting breathing, coughing in supine position, decreased activity tolerance, abdominal distension / anorexia, etc. Typical signs of heart failure include pulmonary moist rales, lower extremity edema, third heart sound, galloping rhythm, jugular vein filling or distention, positive hepatic jugular vein reflux, etc. 3. Patients with elevated plasma NT proBNP level: when diagnosing AHF, plasma NT proBNP level should be stratified according to age and renal insufficiency: NT proBNP > 450 pg / ml when the age is 900 pg / ml when the age is 50-75 years old, NT proBNP > 1800 PG / ml when the age is > 75 years old; NT proBNP > 1200 pg / ml when the creatinine clearance rate is = 50%). Among them, hfmref and HFPEF should meet at least one of the following criteria in addition to typical symptoms and / or signs of heart failure and elevated NT proBNP levels (1) Left ventricular hypertrophy and / or left atrial enlargement, (2) Ventricular diastolic function was abnormal. Left ventricular mass index (LVMI) >= 115 g / m2 (male) or >= 95 g / m2 (female) was the diagnostic criteria for left ventricular hypertrophy; left atrial volume index (Lavi) > 34 ml / m2 or left atrial anteroposterior diameter (LAD) > 40 was the diagnostic criteria for left atrial enlargement The diagnostic criteria of left ventricular diastolic dysfunction were E / a ratio 2, and E '(average) 15 for E / a ratio 1-2. 5. Patients with hospital stay > 72h (3D).

Exclusion criteria

Exclusion criteria: 1. Patients with acute cerebrovascular disease (including acute cerebral infarction and acute cerebral hemorrhage within one month); 2. Patients with acute myocardial infarction (within one month of onset); 3. Patients with uncorrected severe valvular heart disease (e.g. severe aortic stenosis / insufficiency, severe mitral stenosis); 4. Patients with uncorrected severe congenital heart disease; 5. Patients with acute or subacute infective endocarditis; 6. Patients with constrictive pericarditis; 7. Patients with aortic dissection and aneurysm; 8. Patients scheduled for coronary artery bypass grafting within one month; 9. Patients who plan to undergo surgical heart valve replacement within one month; 10. Patients scheduled for heart transplantation or left ventricular assist device implantation within 3 months; 11. Patients with chronic pulmonary heart disease and pulmonary interstitial fibrosis; 12. Patients with decompensated cirrhosis; 13. Patients with renal failure requiring dialysis treatment; 14. Patients with malignant tumors whose expected survival time is less than 1 year; 15. Patients with history of major organ transplantation (such as lung, heart, liver, kidney and bone marrow); 16. Patients with other serious diseases leading to poor prognosis or reduced survival rate, such as severe infection, sepsis, other serious uncontrolled diseases of various systems, have a life expectancy of less than 1 year; 17. The researchers believe that there are medical conditions that are not suitable for the study, including drug or alcohol abuse or serious mental illness, which affect the patient's ability to comply with the protocol or follow-up procedures.

Design outcomes

Primary

MeasureTime frame
soluble suppression of tumorigenicity 2 (sST2);SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactZhang Jian

Fuwai Hospital, Chinese Academy of Medical Sciences

fwzhangjian62@126.com+86 13911102015

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026